Sangamo Therapeutics Stock Forecast

OTC-SGMO's stock price has decreased by -66.4% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

According to 3 analysts polled by S&P Global, Sangamo Therapeutics stock has a consensus rating of "Buy" and an average price target of $1.67. The average 1-year stock price forecast is 882.35% higher than the current stock price, while the lowest is $1.00 (+488.24%) and the highest is $2.00 (+1,076.47%).

Price Target: $1.67 (+882.35%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$1.00	$1.67	$2.00	$2.00
Change	+488.24%	+882.35%	+1076.5%	+1076.5%

Analyst Ratings

The average analyst rating for Sangamo Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Dec '25	Jan '26	Feb '26	Mar '26	Apr '26	May '26
Strong Buy	2	2	2	2	2	2
Buy	0	0	0	0	0	0
Hold	3	2	2	2	2	2
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	5	4	4	4	4	4

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Patrick Trucchio H.C. Wainwright	H.C. Wainwright	Buy Reiterates $5	Buy	Reiterates	$5	+2,841.18%	May 26, 2026
Luca Issi RBC Capital	RBC Capital	Hold Maintains $2	Hold	Maintains	$2	+1,076.47%	May 15, 2026
Unknown Analyst Wells Fargo No rating	Wells Fargo	Hold Maintains $4 → $2	Hold	Maintains	$4 → $2	+1,076.47%	Jan 5, 2026

Financial Forecast

Revenue This Year

55.85M

from 39.55M

41.21%

from 39.55M

Revenue Next Year

129.63M

from 55.85M

132.11%

from 55.85M

EPS This Year

-0.20

from -0.39

EPS Next Year

0.01

from -0.20

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	110.70M	111.30M	176.23M	57.80M	39.55M	55.85M
Revenue Growth	-6.34%	0.54%	58.34%	-67.20%	-31.57%	41.21%
Gross Profit	-120.12M	-138.60M	-54.23M	-53.52M	-73.12M	55.85M
Gross Margin	-108.51%	-124.53%	-30.77%	-92.60%	-184.87%	100.00%
Operating Income	-183.34M	-201.28M	-114.29M	-98.25M	-108.00M	-99.10M
Net Income	-178.29M	-192.28M	-257.83M	-97.94M	-122.93M	-94.10M
EPS	-	-	-	-	-0.39	-0.20
Free Cash Flow	-107.24M	-110.51M	-98.11M	-38.03M	-56.76M	-70.00M
No. Analysts	-	-	-	-	-	2

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	101.7M
Avg	55.9M
Low	10.0M

Revenue Growth

Revenue Growth	2026	2027	2028
High	157.1%
Avg	41.2%
Low	-74.7%

EPS Forecast

EPS	2026	2027	2028
High	-0.20
Avg	-0.20
Low	-0.20

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-